US FDA Grants Orphan Drug Status To Immtech’s Pafuramidine For Treatment Of African Sleeping Sickness
Immtech Pharmaceuticals, Inc. (Amex: IMM) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pafuramidine (DB289) for treating Human African Trypanosomiasis (HAT), also known as African sleeping sickness.
